The ongoing Phase Ib/II ELECTRA trial (NCT05386108) is evaluating elacestrant in combination with abemaciclib for treating brain metastases in ER+/HER2− breast cancer patients (361), suggesting that elacestrant could become a new standard-of-care in this setting. This evidence concerns the gene ESR1 and breast cancer.